

# Discovery and Evaluation of Polymorphisms in the *AKT2* and *AKT3* Promoter Regions for Risk of Korean Lung Cancer

Jae Sook Sung<sup>1,2</sup>, Kyong Hwa Park<sup>3</sup>, Seung Tae Kim<sup>3</sup>, Yeul Hong Kim<sup>1,2,3\*</sup>

<sup>1</sup>Genomic Research Center for Lung and Breast/Ovarian Cancers, Korea University Anam Hospital, Seoul 136-705, Korea,

<sup>2</sup>Division of Brain Korea 21 Program for Biomedical Science, Korea University College of Medicine, Seoul 136-701, Korea,

<sup>3</sup>Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul 136-701, Korea

AKT is a signal transduction protein that plays a central role in the tumorigenesis. There are 3 mammalian isoforms of this serine/threonine protein kinase—AKT1, AKT2, and AKT3—showing a broad tissue distribution. We first discovered 2 novel polymorphisms (AKT2 -9826 C/G and AKT3 -811 A/G), and we confirmed 6 known polymorphisms (AKT2 -9473 C/T, AKT2 -9151 C/T, AKT2 -9025 C/T, AKT2 -8618G/A, AKT3 -675 A/-, and AKT3 -244 C/T) of the *AKT2* and *AKT3* promoter region in 24 blood samples of Korean lung cancer patients using direct sequencing. To evaluate the role of *AKT2* and *AKT3* polymorphisms in the risk of Korean lung cancer, genotypes of the *AKT2* and *AKT3* polymorphisms (AKT2 -9826 C/G, AKT2 -9473 C/T, AKT2 -9151 C/T, AKT2 -9025 C/T, AKT2 -8618G/A, and AKT3 -675 A/-) were determined in 360 lung cancer patients and 360 normal controls. Statistical analyses revealed that the genotypes and haplotypes in the *AKT2* and *AKT3* promoter regions were not significantly associated with the risk of lung cancer in the Korean population. These results suggest that polymorphisms of the *AKT2* and *AKT3* promoter regions do not contribute to the genetic susceptibility to lung cancer in the Korean population.

**Keywords:** AKT, genetic polymorphism, genetic promoter region, lung neoplasms

## Introduction

Lung cancer has been the leading cause of cancer-related deaths in Korea, and its incidence continues to rise [1]. Despite therapeutic advances, the overall 5-year survival remains only 15% [2]. Lung cancer is a multicellular and multistage process that involves a number of genetic changes in oncogenes and tumor suppressor genes. Nevertheless, the prognosis of lung cancer has remained poor despite innovations in diagnostic testing and surgical technique and the development of new chemotherapeutic agents. Recently introduced targeted agents show different responses according to histological subtype, and the efficiency of treatment modalities for lung cancer depends on the time of diagnosis [3]. Therefore, there is a great need for rapid and efficient early detection methods. For developing improved molecular biomarkers for the early detection and prediction of response to chemotherapy, it is important to

identify genetic alterations specific to each subtype of lung cancer. Single-nucleotide polymorphisms (SNPs) represent an important class of genetic variations and affect an individual's susceptibility to disease in certain circumstances [4-6].

Activation of the intracellular survival signal transduction protein AKT, known as protein kinase B, has been proposed as a central signaling event in carcinogenesis and has been shown in experimental models to confer resistance to chemotherapy and radiation [7, 8]. AKT is activated by phosphatidylinositol 3 phosphates, the products of phosphoinositide 3-kinase (PI3K) activity [9]. Additionally, AKT activity is commonly dysregulated in a variety of human tumors because of frequent inactivation of the PTEN tumor suppressor gene, which negatively regulates phosphatidylinositol 3 phosphate levels, and alterations of this gene have been identified in various cancers, including lung cancer [10, 11]. To date, 3 human isoforms of *AKT* have been

Received May 5, 2012; Revised August 3, 2012; Accepted August 4, 2012

\*Corresponding author: Tel: +82-2-920-5569, Fax: +82-2-926-4534, E-mail: yhk0215@korea.ac.kr

Copyright © 2012 by The Korea Genome Organization

© It is identical to the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>).

identified, *AKT1*, *AKT2*, and *AKT3*, which are expressed in lung, breast, colon, and prostate tumor tissues [12].

Somatic mutations of *AKTs* have been reported in endometrial carcinomas, hypoglycemia, and breast cancer [13, 14]. However, somatic mutations in *AKT* families are rare in lung cancer [15, 16]. Previously, it was reported that an *AKT1* polymorphism was not associated with schizophrenia [17, 18]. *AKT1* and *AKT2* polymorphisms have been reported to be related to survival of esophageal cancer [19], and it was reported that an *AKT1* polymorphism was associated with survival in surgically resected non-small cell lung cancer [20]. However, the association between *AKT2* and *AKT3* polymorphisms and the risk of lung cancer has not yet been clarified. This study discovered polymorphisms of the *AKT2* and *AKT3* promoter regions and their relation with the risk of lung cancer in a Korean population.

## Methods

### Study subjects

Between August 2001 and November 2010, blood samples were collected from 720 subjects, including 360 lung cancer patients and 360 normal controls without cancer. Lung cancer patients were recruited from the patient pool at the Genomic Research Center for Lung and Breast/Ovarian Cancer, and control subjects were randomly selected from a pool of healthy volunteers who had visited the Cardiovascular Genome Center and Genomic Research Center for Allergy and Respiratory Diseases. Detailed information on diet, smoking status, drinking status, lifestyle, and medical history were collected by trained interviewers using a structured questionnaire. Out of 360 cases, information was available for 352 on smoking status, 317 on stage, and 343 on cell type, while information was available for 272 on smoking status of 360 controls. All study subjects provided written consent and were ethnic Koreans, and all participating Institutional Review Boards approved the study protocol.

### Preparation of genomic DNA and direct sequencing

Genomic DNA was prepared from peripheral blood samples using a Puregene blood DNA kit (Gentra, Minneapolis, MN, USA), following the manufacturer's protocol.

To identify polymorphisms in the promoter of the *AKT2* and *AKT3* genes, human genomic DNA was isolated from the whole blood of 24 lung cancer patients for direct sequencing, and the promoter region of the *AKT2* and *AKT3* genes was amplified. Polymerase chain reaction (PCR) amplifications were performed on a PTC-225 Peltier Thermal cycler (MJ Research Inc., Waltham, MA, USA) using Ampli-TagGold (Roche, Branchburg, NJ, USA). All amplifications

were performed using 35 cycles of 30 s at 95°C, 1 min at 64°C, and 1 min at 72°C, followed by a single 10-min extension at 72°C. PCR products were purified using the Montage PCR96 Cleanup kit (Millipore, Bedford, MA, USA) and eluted in 20 µL of nuclease-free H<sub>2</sub>O. DNA cycle sequencing was carried out using the BigDye Terminator V 3.1 Cycle Sequencing kit (Perkin Elmer, Foster City, CA, USA). Multiscreen SEQ 384-well filter plates were used for dye removal, and sequences were then analyzed on an Applied Biosystems 3700 (ABI, Foster City, CA, USA). All polymorphisms and sequence alignments were analyzed using Polyphred.

### Genotyping

After direct sequencing of the *AKT2* and *AKT3* genes, we performed genotyping for the 8 polymorphisms of the *AKT2* and *AKT3* genes. The genotypes of the *AKT2* and *AKT3* polymorphisms were screened by TaqMan fluorogenic 5' nuclease assay (ABI). The final volume of the PCR was 5 µL, containing 10 ng of genomic DNA, and 2.5 µL TaqMan Universal PCR Master Mix, with 0.13 µL of 40 × Assay Mix. Thermal cycle conditions were as follows: 50°C for 2 min to activate uracil N-glycosylase and prevent carryover contamination, 95°C for 10 min to activate the DNA polymerase, and 45 cycles of 95°C for 15 s and 60°C for 1 min. All PCRs were performed using 384-well plates on a Dual 384-Well GeneAmp PCR System 9700 (ABI), and the endpoint fluorescent readings were performed on an ABI PRISM 7900 HT Sequence Detection System (ABI). Duplicate samples and negative controls were included to ensure accuracy of genotyping.

### Statistical analysis

Allele frequencies, genotype frequencies, and departures of genotype distributions from Hardy-Weinberg equilibrium (HWE) for each SNP were analyzed using chi-square test or Fisher's exact test. A p-value of <0.05 was considered statistically significant. Linkage disequilibrium (LD) was tested on pairwise combinations of polymorphisms using the absolute value of the standardized measure of LD,  $D'$ , calculated by Haploview version 3.2. The haplotypes and their frequencies were estimated by Haploview version 3.2. Genotype-specific risks were estimated as odds ratios with associated 95% confidence intervals by unconditional logistic regression (SAS Institute Inc., Cary, NC, USA) and adjusted for age, gender, and smoking status.

## Results

Table 1 shows the clinicopathological features of cases and controls. All the clinical characteristics, except for smoking

**Table 1.** Characteristics of the study subjects

Variables	Cases (%)	Controls (%)	p-value
Age (y)	60.14 ± 9.39	60.56 ± 10.28	0.552
Gender			
Male	262 (72.8)	264 (73.3)	0.933
Female	98 (27.2)	96 (26.7)	
Smoking status			
Smoker	253 (71.9)	127 (46.7)	<0.001
Non-smoker	99 (28.1)	145 (53.3)	
Stage			
1-3a	76 (24.0)		
3b-4	241 (76.0)		
Cell type			
Adenocarcinoma (Adcc)	148 (43.1)		
Squamous carcinoma (Sqcc)	110 (32.1)		
Other carcinoma	85 (24.8)		

Other carcinomas include small cell, large cell, mixed cell carcinomas, and undifferentiated carcinomas.


**Table 2.** Polymorphism confirmation of the *AKT2* and *AKT3* promoter region by direct sequencing

Gene	SNP location	rs no.	Frequency
<i>AKT2</i>	-9826 C/G	Novel	C : G = 0.957 : 0.043
	-9473 C/T	rs9636120	C : T = 0.636 : 0.364
	-9151 T/C	rs1991823	T : C = 0.543 : 0.457
	-9025 C/T	rs4239505	C : T = 0.935 : 0.065
	-8618 G/A	rs11669332	G : A = 0.937 : 0.063
<i>AKT3</i>	-811 A/G	Novel	A : G = 0.979 : 0.021
	-675 A/-	rs35835614	A : - = 0.688 : 0.312
	-244 C/T	rs12043115	C : T = 0.978 : 0.022

SNP, single-nucleotide polymorphisms.

status, were not significantly different between the cases and controls. This difference of smoking status was controlled in the multiple logistic regression analysis, adjusted for age, gender, and smoking status.

By direct sequencing of the *AKT2* promoter region in 24 lung cancer patient samples, we identified 1 novel polymorphism (-9826 C/G) and 4 known polymorphisms (-9473 C/T, -9151 C/T, -9025 C/T, and -8618 G/A). Also, we identified 1 novel polymorphism (-811 A/G) and 2 known polymorphisms (-675 A/- and -244 C/T) by direct sequencing in the *AKT3* promoter region (Table 2). The genotype distributions of the polymorphisms were in HWE. Also, LD and haplotypes in the polymorphisms of *AKT2* were calculated. However, the LD and haplotype block in *AKT3* polymorphisms were unidentified because of the low frequency of the *AKT3*-811 G allele and *AKT3*-244 T allele (2.1% and 2.2%, respectively) (Fig. 1). Accordingly, we



**Fig. 1.** Polymorphism location in promoter region and linkage disequilibrium (LD). Coding exons are marked by black blocks, and untranslated regions are marked by white blocks. The first base of the translational site is denoted as nucleotide +1. (A) *AKT2* location of promoter polymorphisms and LD block. (B) *AKT3* location of promoter polymorphisms. The LD of *AKT3* polymorphisms was not identified. \*Further analyses polymorphism sites.

focused on the -675 A/- polymorphism in the *AKT3* promoter region. Further analyses were then performed on the samples from 460 lung cancer patients and 460 controls.

Association of lung cancer risk with *AKT* polymorphisms was then analyzed, revealing no association of the polymorphisms with the risks of lung cancer (Table 3). The association of the polymorphisms with the risk of lung cancer was further examined after stratifying the subjects according to gender and smoking status. However, the subsequent analysis revealed no significant association. Furthermore, the haplotypes of the *AKT2* polymorphisms were not associated with the risks of lung cancer in 3 alternative models (data not shown).

## Discussion

V-akt murine thymoma viral oncogene homolog (*AKT*) is a serine/threonine protein kinase that is activated by PI3K- $\alpha$  and mediates PI3L signaling [21]. A major recurrent mutation (Glu17Lys) in the *AKT1* gene, which encodes protein kinase B, has been identified in several solid tumors, including breast, colon, and ovarian cancers [22]. Overall, the frequency of *AKT1* mutations in non-small cell lung carcinoma (NSCLC) is about 1%, and they have only been identified in squamous cell carcinoma [23]. Also, mutations in the *AKT2* and *AKT3* genes are rare in several tumors, including lung cancer [15].

**Table 3.** Association between *AKT2* and *AKT3* promoter polymorphisms and the risk of lung cancer

Group	Gene	Locus	Genotype	Case (%)	Control (%)	Dominant		Recessive		Co-dominant					
						aOR (95% CI)	p-value	aOR (95% CI)	p-value	aOR (95% CI)	p-value				
Overall	<i>AKT2</i>	-9826 C/G	CC	318 (91.12)	328 (91.88)	1.18 (0.65-2.14)	0.58	0.95 (0.61-1.49)	0.83	0.95 (0.75-1.21)	0.470				
			CG	30 (8.6)	26 (7.28)										
		-9473 C/T	GG	1 (0.29)	3 (0.84)	0.93 (0.66-1.31)	0.666								
			CC	133 (37.68)	141 (41.23)										
		-9151 C/T	CT	161 (45.61)	142 (41.52)	0.97 (0.69-1.38)	0.875					0.80 (0.51-1.24)	0.31	0.92 (0.73-1.17)	0.513
			TT	59 (16.71)	59 (17.25)										
	-9025 C/T	CC	127 (35.88)	117 (32.5)	1.21 (0.61-2.41)	0.592	0.45 (0.03-7.25)	0.572	1.13 (0.59-2.16)	0.706					
		CT	172 (48.59)	158 (43.89)											
	<i>AKT3</i>	-675 A/-	TT	55 (15.54)	85 (23.61)	1.23 (0.75-2.12)	0.385	0.71 (0.06-7.94)	0.778	1.21 (0.74-1.96)	0.449				
			GG	313 (87.43)	319 (90.63)										
		GA	44 (12.29)	29 (8.24)											
		AA	1 (0.28)	4 (1.14)											
	Male	<i>AKT2</i>	-9826 C/G	AA	181 (50.84)	193 (56.76)	1.07 (0.77-1.50)	0.673	0.57 (0.30-1.10)	0.094	0.96 (0.73-1.25)	0.734			
				A-	154 (43.26)	115 (33.82)									
-9473 C/T			-	21 (5.9)	32 (9.41)	1.40 (0.62-3.15)	0.423								
			CC	235 (92.16)	242 (92.72)										
-9151 C/T			CG	20 (7.84)	16 (6.13)	0.89 (0.58-1.37)	0.598	1.02 (0.60-1.74)					0.933	0.96 (0.72-1.27)	0.760
			CT	114 (44.36)	97 (39.27)										
-9025 C/T		TT	48 (18.68)	47 (19.03)	0.96 (0.63-1.46)	0.841	0.78 (0.50-1.36)	0.387	0.92 (0.68-1.23)	0.555					
		CC	98 (38.28)	94 (35.61)											
<i>AKT3</i>		-675 A/-	CT	120 (46.88)	105 (39.77)	1.90 (0.77-4.71)	0.167	0.42 (0.03-6.70)	0.535	1.59 (0.70-3.66)	0.271				
			TT	38 (14.84)	65 (24.62)										
	-8618 G/A	CC	239 (91.92)	249 (95.4)	1.31 (0.66-2.60)	0.443									
		CT	20 (7.69)	11 (4.21)											
<i>AKT3</i>	-675 A/-	TT	1 (0.38)	1 (0.38)	1.26 (0.83-1.90)	0.281	0.54 (0.23-1.12)	0.096	1.02 (0.74-1.41)	0.901					
		GG	231 (88.51)	236 (91.83)											
	GA	30 (11.49)	19 (7.39)												
	-	17 (6.56)	29 (11.89)												

Table 3. Continued

Group	Gene	Locus	Genotype	Case (%)	Control (%)	Dominant		Recessive		Co-dominant				
						aOR (95% CI)	p-value	aOR (95% CI)	p-value	aOR (95% CI)	p-value			
Female	AKT2	-9826 C/G	CC	83 (88.3)	86 (89.58)	1.06 (0.41-2.73)	0.906	0.991	1.14 (0.47-2.77)	0.768	CG	10 (10.64)	10 (10.42)	
			GG	1 (1.06)	0 (0)									
		-9473 C/T	CC	38 (39.58)	38 (40)	1.10 (0.60-2.04)	0.760	1.02 (0.41-2.56)	0.960	1.06 (0.67-1.67)	0.803	CT	47 (48.96)	45 (47.37)
			TT	11 (11.46)	12 (12.63)									
		-9151 C/T	CC	29 (29.59)	23 (23.96)	0.78 (0.40-1.52)	0.466	0.79 (0.36-1.71)	0.550	0.83 (0.53-1.29)	0.405	CT	52 (53.06)	53 (55.21)
			TT	17 (17.35)	20 (20.83)									
	-9025 C/T	CC	94 (96.91)	89 (92.71)	0.39 (0.09-1.61)	0.192			0.39 (0.09-1.61)	0.192	CT	3 (3.09)	7 (7.29)	
		TT	0 (0)	0 (0)										
	-8618 G/A	GG	82 (84.54)	83 (87.37)	1.17 (0.50-2.74)	0.718	0.50 (0.04-5.74)	0.575	1.05 (0.51-2.17)	0.897	GA	14 (14.43)	10 (10.53)	
		AA	1 (1.03)	2 (2.11)										
	AKT3	-675 A/-	AA	56 (57.73)	55 (57.29)	0.92 (0.50-1.67)	0.778	1.02 (0.21-5.03)	0.984	0.94 (0.56-1.56)	0.811	A-	37 (38.14)	38 (39.58)
			-	4 (4.12)	3 (3.13)									
	Smoker	AKT2	-9826 C/G	CC	226 (92.24)	119 (95.2)	1.60 (0.61-4.20)	0.337		1.60 (0.61-4.20)	0.337	CG	19 (7.76)	6 (4.8)
				GG	0 (0)	0 (0)								
-9473 C/T			CC	90 (36.29)	45 (36.29)	0.98 (0.62-1.55)	0.935	0.85 (0.49-1.49)	0.572	0.95 (0.70-1.28)	0.720	CT	115 (46.37)	53 (42.74)
			TT	43 (17.34)	26 (20.97)									
-9151 C/T			CC	95 (38.46)	48 (37.8)	0.97 (0.62-1.52)	0.885	0.70 (0.39-1.27)	0.239	0.89 (0.65-1.22)	0.476	CT	116 (46.96)	56 (44.09)
			TT	36 (14.57)	23 (18.11)									
-9025 C/T		CC	229 (91.6)	122 (97.6)	3.36 (0.98-11.54)	0.055	0.40 (0.03-6.44)	0.517	2.35 (0.82-6.76)	0.113	CT	20 (8)	2 (1.6)	
		TT	1 (0.4)	1 (0.8)										
-8618 G/A		GG	222 (88.1)	116 (92.06)	1.43 (0.67-3.07)	0.356			1.43 (0.67-3.07)	0.356	GA	30 (11.9)	10 (7.94)	
		AA	0 (0)	0 (0)										
AKT3		-675 A/-	AA	120 (48)	71 (56.35)	1.44 (0.93-2.23)	0.105	0.48 (0.23-1.02)	0.055	1.07 (0.76-1.51)	0.682	A-	114 (45.6)	39 (30.95)
			-	16 (6.4)	16 (12.7)									

**Table 3.** Continued

Group	Gene	Locus	Genotype	Case (%)	Control (%)	Dominant		Recessive		Co-dominant					
						aOR (95% CI)	p-value	aOR (95% CI)	p-value	aOR (95% CI)	p-value				
Non-smoker	AKT2	-9826 C/G	CC	87 (88.78)	128 (88.28)	0.97 (0.43-2.18)	0.947	0.991	1.06 (0.50-2.27)	0.875					
			CG	10 (10.2)	17 (11.72)										
			GG	1 (1.02)	0 (0)										
			-9473 C/T	CC	39 (40.21)						52 (36.36)				
		CT		43 (44.33)	72 (50.35)						0.85 (0.50-1.45)	0.556	1.15 (0.55-2.40)	0.712	0.96 (0.65-1.40)
			TT	15 (15.46)	19 (13.29)										
			-9151 C/T	CC	30 (30.3)						45 (31.03)				
	CT	52 (52.53)		73 (50.34)	1.09 (0.62-1.91)	0.773	0.92 (0.47-1.81)	0.816	1.01 (0.70-1.45)	0.950					
		TT	17 (17.17)	27 (18.62)											
		-9025 C/T	CC	96 (96.97)	133 (91.72)										
	CT		3 (3.03)	12 (8.28)	0.35 (0.10-1.28)	0.114			0.35 (0.10-1.28)	0.114					
	AKT3	-675 A/-	-8618 G/A	TT	0 (0)	0 (0)									
				GG	85 (85.86)	125 (86.81)									
			GA	13 (13.13)	17 (11.81)	1.11 (0.52-2.33)	0.792	0.74 (0.07-8.29)	0.806	1.06 (0.55-2.04)	0.871				
AA			1 (1.01)	2 (1.39)											
AA			58 (59.18)	73 (51.05)											
	A-	36 (36.73)	64 (44.76)	0.72 (0.42-1.20)	0.206	0.91 (0.25-3.35)	0.888	0.77 (0.50-1.21)	0.255						
	-	4 (4.08)	6 (4.2)												

Adjusted odds ratio (aOR) and p-values were calculated by unconditional logistic regression, adjusted for age, gender, and smoking history.

Logistic regression models were used to calculate the aORs, 95% confidence intervals (CIs), and the corresponding p-values of co-dominant (minor allele homozygotes vs. heterozygotes vs. major allele homozygotes), dominant (minor allele homozygotes + heterozygotes vs. major allele homozygotes), and recessive (minor allele homozygotes vs. heterozygotes + major allele homozygotes) models after controlling for age, gender, and smoking status.

Recently, several polymorphisms in the *AKT1* gene have been reported in relation to human disease [24-26]. Kim et al. [20] first reported that the *AKT1* polymorphisms could be used as prognostic markers for patients with early-stage NSCLC. However, there has been no study on the association between lung cancer risk and polymorphisms of *AKT2* and *AKT3*. In this study, we investigated the association between *AKT2* and *AKT3* polymorphisms and the risk of lung cancer in the Korean population. The genotypes and haplotypes of the *AKT2* and *AKT3* genes were determined in 720 Koreans to evaluate the role of the *AKT2* and *AKT3* polymorphisms in the risk of lung cancer; however, the results revealed no significant difference between lung cancer patients and normal controls. Also, by TFSEARCH (version 1.3) analysis of the *AKT2* and *AKT3* polymorphism regions, the location of these variants did not have sequences for transcription factor binding sites. This result suggests that polymorphisms of the *AKT2* and *AKT3* promoter region are unlikely to play an important role in the susceptibility to

lung cancer.

Polymorphisms often show ethnic variation [6, 27]. In the present study, we observed the frequencies of 5 polymorphisms in the *AKT2* promoter region, and we observed frequencies of 3 polymorphisms in the *AKT3* promoter region in 24 Korean populations using direct sequencing. In the direct sequencing result, we detected no frequencies in another known polymorphisms (*AKT2*: rs11666690, rs11665880, rs35814223, rs34408497, rs35408040, rs10418387; *AKT3*: rs11588441, rs6679386, rs41267521). The frequencies of *AKT2* promoter polymorphisms showed similar frequencies in the Asian ethnic groups (Han Chinese and Japanese) of the dbSNP database (www.ncbi.nlm.nih.gov/SNP). The frequency of the minor allele of rs35835614 in the *AKT3* gene was 0.275; however, the frequency of this polymorphism has not been reported in the dbSNP database (www.ncbi.nlm.nih.gov/SNP). A series of our previous studies showed that polymorphisms of oncogenes, tumor suppressor genes, and receptor tyrosine kinases are related

to lung cancer risk [6, 28, 29]. Recently, we reported that *STK11* and *PIK3CA* polymorphisms are not related to genetic susceptibility to lung cancer [30, 31]. The genotypes of the *AKT2* and *AKT3* promoter polymorphisms, determined in 720 Koreans in the present study, revealed no significant difference between lung cancer patients and normal controls. To our best knowledge, this is the first study on the association of *AKT2* and *AKT3* promoter polymorphisms and the risk of lung cancer in a Korean population.

## Acknowledgments

This study was supported by the Korea Healthcare Technology R&D Project, Ministry of Health, Welfare and Family Affairs, Republic of Korea (Grant No. A010250).

## References

- Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, *et al.* Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. *Cancer Res Treat* 2011;43:1-11.
- Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, *et al.* Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med* 2002;346:92-98.
- Devouassoux G, Pison C, Drouet C, Pin I, Brambilla C, Brambilla E. Early lung leukocyte infiltration, HLA and adhesion molecule expression predict chronic rejection. *Transpl Immunol* 2001;8:229-236.
- Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, *et al.* Characterization of single-nucleotide polymorphisms in coding regions of human genes. *Nat Genet* 1999;22:231-238.
- Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. *Nucleic Acids Res* 2002;30:3894-3900.
- Sung JS, Han SG, Whang YM, Shin ES, Lee JW, Lee HJ, *et al.* Putative association of the single nucleotide polymorphisms in *RASSF1A* promoter with Korean lung cancer. *Lung Cancer* 2008;61:301-308.
- Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. *Nat Rev Cancer* 2002;2:489-501.
- Brogard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. *Cancer Res* 2001;61:3986-3997.
- Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. *Biochem J* 1998;335(Pt 1):1-13.
- Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. *Proc Natl Acad Sci U S A* 1999;96:4240-4245.
- Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. *Cell* 2000;100:387-390.
- Zinda MJ, Johnson MA, Paul JD, Horn C, Konicek BW, Lu ZH, *et al.* *AKT-1*, *-2*, and *-3* are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. *Clin Cancer Res* 2001;7:2475-2479.
- Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y, *et al.* The oncogenic mutation in the pleckstrin homology domain of *AKT1* in endometrial carcinomas. *Br J Cancer* 2009;101:145-148.
- Hussain K, Challis B, Rocha N, Payne F, Minic M, Thompson A, *et al.* An activating mutation of *AKT2* and human hypoglycemia. *Science* 2011;334:474.
- Soung YH, Lee JW, Nam SW, Lee JY, Yoo NJ, Lee SH. Mutational analysis of *AKT1*, *AKT2* and *AKT3* genes in common human carcinomas. *Oncology* 2006;70:285-289.
- Pao W, Girard N. New driver mutations in non-small-cell lung cancer. *Lancet Oncol* 2011;12:175-180.
- Liu YC, Huang CL, Wu PL, Chang YC, Huang CH, Lane HY. Lack of association between *AKT1* variances versus clinical manifestations and social function in patients with schizophrenia. *J Psychopharmacol* 2009;23:937-943.
- Lee KY, Joo EJ, Jeong SH, Kang UG, Roh MS, Kim SH, *et al.* No association between *AKT1* polymorphism and schizophrenia: a case-control study in a Korean population and a meta-analysis. *Neurosci Res* 2010;66:238-245.
- Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, *et al.* Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. *J Clin Oncol* 2009;27:857-871.
- Kim MJ, Kang HG, Lee SY, Jeon HS, Lee WK, Park JY, *et al.* *AKT1* polymorphisms and survival of early stage non-small cell lung cancer. *J Surg Oncol* 2012;105:167-174.
- Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. *Proc Natl Acad Sci U S A* 2001;98:10983-10985.
- Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, *et al.* A transforming mutation in the pleckstrin homology domain of *AKT1* in cancer. *Nature* 2007;448:439-444.
- Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S, *et al.* Activating E17K mutation in the gene encoding the protein kinase *AKT1* in a subset of squamous cell carcinoma of the lung. *Cell Cycle* 2008;7:665-669.
- Harris SL, Gil G, Robins H, Hu W, Hirshfield K, Bond E, *et al.* Detection of functional single-nucleotide polymorphisms that affect apoptosis. *Proc Natl Acad Sci U S A* 2005;102:16297-16302.
- Zai CC, Romano-Silva MA, Hwang R, Zai GC, Deluca V, Müller DJ, *et al.* Genetic study of eight *AKT1* gene polymorphisms and their interaction with *DRD2* gene polymorphisms in tardive dyskinesia. *Schizophr Res* 2008;106:248-252.
- Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y, *et al.* Association of *AKT1* with schizophrenia confirmed in a Japanese population. *Biol Psychiatry* 2004;56:698-700.
- Kim JH, Kim H, Lee KY, Choe KH, Ryu JS, Yoon HI, *et al.* Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer risk. *Hum Mol Genet* 2006;15:1181-1186.
- Jo UH, Han SG, Seo JH, Park KH, Lee JW, Lee HJ, *et al.* The ge-

- netic polymorphisms of *HER-2* and the risk of lung cancer in a Korean population. *BMC Cancer* 2008;8:359.
29. Choi HS, Lee Y, Park KH, Sung JS, Lee JE, Shin ES, et al. Single-nucleotide polymorphisms in the promoter of the *CDK5* gene and lung cancer risk in a Korean population. *J Hum Genet* 2009;54:298-303.
30. Sung JS, Park KH, Kim ST, Seo JH, Shin SW, Kim JS, et al. No association between *PIK3CA* polymorphism and lung cancer risk in the Korean population. *Genomics Inform* 2010;8:194-200.
31. Sung JS, Whang YM, Park KH, Ryu JS, Choi JG, Seo JH, et al. No association between promoter polymorphism of *STK11* gene and lung cancer risk in the Korean population. *Cancer Res Treat* 2009;41:211-217.